ACADIA Pharmaceuticals (ACAD) : Ray Gerald L Associates Ltd scooped up 4,400 additional shares in ACADIA Pharmaceuticals during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 159,590 shares of ACADIA Pharmaceuticals which is valued at $5,006,338.ACADIA Pharmaceuticals makes up approximately 0.77% of Ray Gerald L Associates Ltd’s portfolio.
Other Hedge Funds, Including , Baker Bros. Advisors Lp boosted its stake in ACAD in the latest quarter, The investment management firm added 3,732,396 additional shares and now holds a total of 24,213,838 shares of ACADIA Pharmaceuticals which is valued at $759,588,098. ACADIA Pharmaceuticals makes up approx 8.48% of Baker Bros. Advisors Lp’s portfolio. Bronfman E.l. Rothschild added ACAD to its portfolio by purchasing 5 company shares during the most recent quarter which is valued at $157.Profund Advisors reduced its stake in ACAD by selling 3,523 shares or 6.81% in the most recent quarter. The Hedge Fund company now holds 48,181 shares of ACAD which is valued at $1,511,438. ACADIA Pharmaceuticals makes up approx 0.07% of Profund Advisors’s portfolio.Norges Bank boosted its stake in ACAD in the latest quarter, The investment management firm added 86,004 additional shares and now holds a total of 789,447 shares of ACADIA Pharmaceuticals which is valued at $24,764,952. ACADIA Pharmaceuticals makes up approx 0.01% of Norges Bank’s portfolio.Cable Hill Partners reduced its stake in ACAD by selling 5 shares or 3.36% in the most recent quarter. The Hedge Fund company now holds 144 shares of ACAD which is valued at $5,255.
ACADIA Pharmaceuticals closed down -0.03 points or -0.09% at $32.1 with 13,67,940 shares getting traded on Thursday. Post opening the session at $32.19, the shares hit an intraday low of $31.525 and an intraday high of $32.69 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, ACADIA Pharmaceuticals reported $-0.63 EPS for the quarter, missing the analyst consensus estimate by $ -0.16 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.47. The company had revenue of $.97 million for the quarter, compared to analysts expectations of $.71 million. The company’s revenue was up 96900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.39 EPS.
Many Wall Street Analysts have commented on ACADIA Pharmaceuticals. ACADIA Pharmaceuticals was Downgraded by BofA/Merrill to ” Neutral” on Jun 22, 2016.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis Alzheimers disease psychosis Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan has discovered and engaged in the development of small-molecule product candidates such as alpha adrenergic agonists and muscarinic receptors.